MoonLake Reports Phase 3 VELA Trial Results for HS Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Clinical Trial Success: In the Week 52 results of the VELA trials, 67.2% of patients achieved HiSCR75 and 33.1% reached HiSCR100, demonstrating sonelokimab's superior efficacy in treating moderate-to-severe HS, potentially positioning it as a best-in-class therapy.
- Quality of Life Improvement: Patients reported a mean HiSQOL score improvement of 15.0 points at Week 52, indicating significant enhancements in their quality of life, reflecting sonelokimab's potential in alleviating symptoms and improving daily living for HS patients.
- Sustained Safety Profile: No new safety signals were detected in the VELA trials, confirming sonelokimab's favorable safety profile over long-term use, thereby enhancing its credibility as a candidate for HS treatment.
- Future Plans: MoonLake intends to submit a Biologics License Application (BLA) by the end of September 2026 and will host an Investor Day webcast on June 22, 2026, to discuss clinical data and future developments, showcasing the company's commitment to HS treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLTX
Wall Street analysts forecast MLTX stock price to rise
12 Analyst Rating
9 Buy
2 Hold
1 Sell
Moderate Buy
Current: 19.190
Low
5.00
Averages
24.10
High
45.00
Current: 19.190
Low
5.00
Averages
24.10
High
45.00
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MoonLake Reports Phase 3 VELA Trial Results for HS Treatment
- Clinical Trial Success: In the Week 52 results of the VELA trials, 67.2% of patients achieved HiSCR75 and 33.1% reached HiSCR100, demonstrating sonelokimab's superior efficacy in treating moderate-to-severe HS, potentially positioning it as a best-in-class therapy.
- Quality of Life Improvement: Patients reported a mean HiSQOL score improvement of 15.0 points at Week 52, indicating significant enhancements in their quality of life, reflecting sonelokimab's potential in alleviating symptoms and improving daily living for HS patients.
- Sustained Safety Profile: No new safety signals were detected in the VELA trials, confirming sonelokimab's favorable safety profile over long-term use, thereby enhancing its credibility as a candidate for HS treatment.
- Future Plans: MoonLake intends to submit a Biologics License Application (BLA) by the end of September 2026 and will host an Investor Day webcast on June 22, 2026, to discuss clinical data and future developments, showcasing the company's commitment to HS treatment.
See More
MoonLake Immunotherapeutics Reports Strong VELA Trial Results for Sonelokimab
- Clinical Trial Results: At Week 52 of the VELA trials, 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100 with sonelokimab, demonstrating its superior efficacy in treating moderate-to-severe hidradenitis suppurativa compared to competitors.
- Quality of Life Improvement: Patients reported a mean improvement of 15.0 points in HS-specific quality of life scores (HiSQOL) at Week 52, indicating a shift from 'severe' to 'mild' impairment, which not only enhances patient satisfaction but also strengthens the company's competitive position in the market.
- Sustained Safety Profile: No new safety signals were detected in the VELA trials, confirming the long-term safety of sonelokimab, which supports its future marketability and acceptance among healthcare providers.
- Future Plans: MoonLake plans to submit a Biologics License Application (BLA) by the end of September 2026 and will hold an Investor Day webcast on June 22, 2026, to discuss these findings and outline its commercialization strategy.
See More
MoonLake's Sonelokimab Shows Promising Phase 3 Results for Hidradenitis Suppurativa
- Clinical Trial Success: MoonLake's experimental drug sonelokimab demonstrated that 67.2% of patients achieved at least a 75% reduction in inflammatory lesions after 52 weeks in two Phase 3 trials, indicating significant efficacy in treating hidradenitis suppurativa and positioning it as a strong market competitor.
- Regulatory Submission Plans: The company plans to submit a Biologics License Application (BLA) to the U.S. FDA by the end of September, with potential market entry by late 2027 or earlier if granted Priority Review, highlighting its commercial potential.
- Adolescent Patient Data: In the VELA-TEEN study involving adolescent patients, nearly 68% achieved HiSCR75 and approximately 45% reached HiSCR100 at 24 weeks, suggesting the drug's effectiveness in younger populations and potential market expansion.
- Improved Quality of Life: Patient-reported outcomes indicated substantial improvements in quality of life, with nearly half of participants experiencing at least a three-point improvement on a standardized pain scale, demonstrating that sonelokimab positively impacts both clinical and subjective patient experiences.
See More
MoonLake Immunotherapeutics Set for Key Clinical Data Release
- Clinical Trial Progress: MoonLake's two large late-stage trials for hidradenitis suppurativa involved approximately 838 patients, with one trial meeting its primary goal while the other narrowly missed due to an unusually high placebo response rate, highlighting the complexity of clinical outcomes.
- Data Release Expectations: Full 52-week results from both trials are anticipated in Q2 2026, which will help assess the drug's long-term efficacy and could significantly impact future market performance.
- Acquisition Rumors: Merck is viewed as a potential acquirer of MoonLake, having made a non-binding offer exceeding $3 billion in 2025, which was rejected by MoonLake, yet discussions may resume, indicating strong market interest in the company.
- Investor Sentiment Shift: Over the past 24 hours, retail sentiment around MLTX shifted from 'bearish' to 'bullish', with message volume rising significantly, reflecting investor optimism regarding the upcoming clinical data, which could drive stock price increases.
See More
MoonLake Immunotherapeutics Stock Outlook Remains Positive
- Analyst Rating Reaffirmed: H.C. Wainwright reiterated its 'Buy' rating and set a $45 price target for MoonLake (MLTX), implying a 150% upside from current levels, reflecting strong analyst confidence in the company's future performance.
- Impressive Clinical Data: At the EULAR conference, Sonelokimab demonstrated a 77% symptom improvement rate in patients with axial spondyloarthritis, with over half achieving partial remission by Week 12, indicating significant clinical efficacy of the drug.
- Key FDA Progress: MoonLake reached an agreement with the FDA during its final pre-BLA meeting, planning to submit the BLA for hidradenitis suppurativa by the end of September, with a decision on Priority Review expected by the end of November, further advancing the company's product launch timeline.
- Investors Eye Future Catalysts: Investors are eagerly anticipating clinical milestones for MLTX, with 52-week data from the Vela-1 and Vela-2 studies expected in Q2, showcasing strong market confidence in the company's growth potential.
See More
MoonLake CFO Sells Shares Amid Market Volatility
- Share Sale Details: On May 11, 2026, MoonLake Immunotherapeutics CFO Matthias Bodenstedt sold 13,653 shares at approximately $20.02 each, totaling around $273,000, which represented a 1.1% reduction in his direct holdings from 1,186,084 to 1,172,431 shares.
- Transaction Context: This was a direct-only transaction with no indirect or derivative activities, indicating that Bodenstedt maintains a significant stake in the company, reinforcing his confidence despite the sale.
- Market Reaction and Risks: While the sale is part of a normal Rule 10b5-1 trading plan, MoonLake is considered a high-risk investment; however, many analysts still rate it a Buy, as its lead drug sonelokimab shows positive trial results and is expected to be approved for commercial launch by late 2027.
- Investor Recommendations: Aggressive investors who can tolerate high-risk stocks may find MoonLake appealing, but conservative investors are likely to prefer allocating their capital elsewhere, especially given the company's pre-revenue status.
See More
MoonLake Reports Phase 3 VELA Trial Results for HS Treatment
- Clinical Trial Success: In the Week 52 results of the VELA trials, 67.2% of patients achieved HiSCR75 and 33.1% reached HiSCR100, demonstrating sonelokimab's superior efficacy in treating moderate-to-severe HS, potentially positioning it as a best-in-class therapy.
- Quality of Life Improvement: Patients reported a mean HiSQOL score improvement of 15.0 points at Week 52, indicating significant enhancements in their quality of life, reflecting sonelokimab's potential in alleviating symptoms and improving daily living for HS patients.
- Sustained Safety Profile: No new safety signals were detected in the VELA trials, confirming sonelokimab's favorable safety profile over long-term use, thereby enhancing its credibility as a candidate for HS treatment.
- Future Plans: MoonLake intends to submit a Biologics License Application (BLA) by the end of September 2026 and will host an Investor Day webcast on June 22, 2026, to discuss clinical data and future developments, showcasing the company's commitment to HS treatment.
See More
MoonLake Immunotherapeutics Reports Strong VELA Trial Results for Sonelokimab
- Clinical Trial Results: At Week 52 of the VELA trials, 67.2% of patients achieved HiSCR75 and 33.1% achieved HiSCR100 with sonelokimab, demonstrating its superior efficacy in treating moderate-to-severe hidradenitis suppurativa compared to competitors.
- Quality of Life Improvement: Patients reported a mean improvement of 15.0 points in HS-specific quality of life scores (HiSQOL) at Week 52, indicating a shift from 'severe' to 'mild' impairment, which not only enhances patient satisfaction but also strengthens the company's competitive position in the market.
- Sustained Safety Profile: No new safety signals were detected in the VELA trials, confirming the long-term safety of sonelokimab, which supports its future marketability and acceptance among healthcare providers.
- Future Plans: MoonLake plans to submit a Biologics License Application (BLA) by the end of September 2026 and will hold an Investor Day webcast on June 22, 2026, to discuss these findings and outline its commercialization strategy.
See More
MoonLake's Sonelokimab Shows Promising Phase 3 Results for Hidradenitis Suppurativa
- Clinical Trial Success: MoonLake's experimental drug sonelokimab demonstrated that 67.2% of patients achieved at least a 75% reduction in inflammatory lesions after 52 weeks in two Phase 3 trials, indicating significant efficacy in treating hidradenitis suppurativa and positioning it as a strong market competitor.
- Regulatory Submission Plans: The company plans to submit a Biologics License Application (BLA) to the U.S. FDA by the end of September, with potential market entry by late 2027 or earlier if granted Priority Review, highlighting its commercial potential.
- Adolescent Patient Data: In the VELA-TEEN study involving adolescent patients, nearly 68% achieved HiSCR75 and approximately 45% reached HiSCR100 at 24 weeks, suggesting the drug's effectiveness in younger populations and potential market expansion.
- Improved Quality of Life: Patient-reported outcomes indicated substantial improvements in quality of life, with nearly half of participants experiencing at least a three-point improvement on a standardized pain scale, demonstrating that sonelokimab positively impacts both clinical and subjective patient experiences.
See More
MoonLake Immunotherapeutics Set for Key Clinical Data Release
- Clinical Trial Progress: MoonLake's two large late-stage trials for hidradenitis suppurativa involved approximately 838 patients, with one trial meeting its primary goal while the other narrowly missed due to an unusually high placebo response rate, highlighting the complexity of clinical outcomes.
- Data Release Expectations: Full 52-week results from both trials are anticipated in Q2 2026, which will help assess the drug's long-term efficacy and could significantly impact future market performance.
- Acquisition Rumors: Merck is viewed as a potential acquirer of MoonLake, having made a non-binding offer exceeding $3 billion in 2025, which was rejected by MoonLake, yet discussions may resume, indicating strong market interest in the company.
- Investor Sentiment Shift: Over the past 24 hours, retail sentiment around MLTX shifted from 'bearish' to 'bullish', with message volume rising significantly, reflecting investor optimism regarding the upcoming clinical data, which could drive stock price increases.
See More
MoonLake Immunotherapeutics Stock Outlook Remains Positive
- Analyst Rating Reaffirmed: H.C. Wainwright reiterated its 'Buy' rating and set a $45 price target for MoonLake (MLTX), implying a 150% upside from current levels, reflecting strong analyst confidence in the company's future performance.
- Impressive Clinical Data: At the EULAR conference, Sonelokimab demonstrated a 77% symptom improvement rate in patients with axial spondyloarthritis, with over half achieving partial remission by Week 12, indicating significant clinical efficacy of the drug.
- Key FDA Progress: MoonLake reached an agreement with the FDA during its final pre-BLA meeting, planning to submit the BLA for hidradenitis suppurativa by the end of September, with a decision on Priority Review expected by the end of November, further advancing the company's product launch timeline.
- Investors Eye Future Catalysts: Investors are eagerly anticipating clinical milestones for MLTX, with 52-week data from the Vela-1 and Vela-2 studies expected in Q2, showcasing strong market confidence in the company's growth potential.
See More
MoonLake CFO Sells Shares Amid Market Volatility
- Share Sale Details: On May 11, 2026, MoonLake Immunotherapeutics CFO Matthias Bodenstedt sold 13,653 shares at approximately $20.02 each, totaling around $273,000, which represented a 1.1% reduction in his direct holdings from 1,186,084 to 1,172,431 shares.
- Transaction Context: This was a direct-only transaction with no indirect or derivative activities, indicating that Bodenstedt maintains a significant stake in the company, reinforcing his confidence despite the sale.
- Market Reaction and Risks: While the sale is part of a normal Rule 10b5-1 trading plan, MoonLake is considered a high-risk investment; however, many analysts still rate it a Buy, as its lead drug sonelokimab shows positive trial results and is expected to be approved for commercial launch by late 2027.
- Investor Recommendations: Aggressive investors who can tolerate high-risk stocks may find MoonLake appealing, but conservative investors are likely to prefer allocating their capital elsewhere, especially given the company's pre-revenue status.
See More
